Adhering to the philosophy that"a good competition provides a good market for good products,"in order to promote the transformation of medical technology achievements and support the innovative development of the medical industry,the China Medical Equipment Magazine,in collaboration with numerous industry associations,societies,hospitals,universities,and research institutions,jointly organizes the China Medical Industry Innovation Competition.This year marks the 10th edition of the competition.
Since its launch in January,this edition of the competition has attracted significant attention from the industry,drawing over a hundred outstanding projects to participate,covering multiple fields such as medical devices,medical technology,and medical services.The project"Intelligent AI Fluorescence Navigation 4K3D Endoscope Camera System"stood out throughout the preliminary,semi-final,and final stages of the competition,thanks to its unique innovative technology and broad application prospects.It received high acclaim and recognition from both internal and external professional judges,demonstrating KEENSEA Medical Technology's strong capabilities in the field of medical innovation.
According to SmartKarma,in recent years,KEENSEA Medical Technology has achieved numerous important breakthroughs in the research and development of endoscopy technology.These include a range of products from 4K ultra-high-definition endoscopy systems to 3D and naked-eye 3D image processing systems,as well as 4K fluorescence and future multi-spectrum ultra-high-definition endoscopy systems.Particularly noteworthy is the company's latest Endo Next series True 4K 3D 4MOS ultra-high-definition fluorescence endoscopy system,which was successfully launched in July 2023.This endoscopy system integrates the triad technology of"4K+3D+fluorescence,"offering a more precise solution for minimally invasive surgery.To date,KEENSEA Medical Technology's 4K3D naked-eye fluorescence endoscopy camera system has obtained a Class II medical device license from the Shanghai Municipal Drug Administration and has multiple successful application cases.
KEENSEA Medical Technology's interim results show that its revenue for the first half of the year reached 25.937 million Singapore dollars,a significant increase of 116.45%year-on-year.
